Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

17.0K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

1.4K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.4K
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

4.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
4.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Highly Specific Inhibition of <i>c-Myc</i> Oncogene Expression through Shifting the G-Quadruplex toward a Triplex Structure.

Journal of medicinal chemistry·2025
Same author

Towards improved anticancer properties of the G-quadruplex-forming T40231 aptamer through increased flexibility of nucleoside residues.

Scientific reports·2025
Same author

A community child and adolescent psychiatry fellowship for nurse practitioners.

Archives of psychiatric nursing·2025
Same author

Thermodynamic control of mismatch discrimination for extensive splicing regulation of PKM pre-mRNA.

RNA (New York, N.Y.)·2025
Same author

Switching off cancer - An overview of G-quadruplex and i-motif functional role in oncogene expression.

Bioorganic & medicinal chemistry letters·2024
Same author

Revisiting the role of behavior-mediated structuring in the survival of populations in hostile environments.

Communications biology·2024

Related Experiment Video

Updated: Sep 10, 2025

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids
09:04

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids

Published on: September 21, 2017

9.6K

Modified Nucleotides in Bifunctional Antisense Oligonucleotides: Exploring their Anticancer Potential.

Natalia Bartyś1, Anna Pasternak1, Jolanta Lisowiec-Wąchnicka1

  • 1Institute of Bioorganic Chemistry, Polish Academy of Sciences, Noskowskiego 12/14, 61-704, Poznan, Poland.

Chemmedchem
|August 21, 2025
PubMed
Summary

Bifunctional antisense oligonucleotides (BASOs) with specific chemical modifications, like β-L-RNA and unlocked nucleic acid, enhance anticancer properties by regulating gene splicing and reducing cancer cell proliferation and motility.

Keywords:
alternative splicingbifunctional antisense oligonucleotidescancer cell linemodified nucleotidessplicing regulation

More Related Videos

Author Spotlight: Characterizing Novel Enzymes from Extremophiles and Common Pathogens to Understand DNA Repair and Replication
05:33

Author Spotlight: Characterizing Novel Enzymes from Extremophiles and Common Pathogens to Understand DNA Repair and Replication

Published on: July 5, 2024

792
Nucleoside Triphosphates - From Synthesis to Biochemical Characterization
15:22

Nucleoside Triphosphates - From Synthesis to Biochemical Characterization

Published on: April 3, 2014

17.2K

Related Experiment Videos

Last Updated: Sep 10, 2025

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids
09:04

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids

Published on: September 21, 2017

9.6K
Author Spotlight: Characterizing Novel Enzymes from Extremophiles and Common Pathogens to Understand DNA Repair and Replication
05:33

Author Spotlight: Characterizing Novel Enzymes from Extremophiles and Common Pathogens to Understand DNA Repair and Replication

Published on: July 5, 2024

792
Nucleoside Triphosphates - From Synthesis to Biochemical Characterization
15:22

Nucleoside Triphosphates - From Synthesis to Biochemical Characterization

Published on: April 3, 2014

17.2K

Area of Science:

  • Molecular Biology
  • Biochemistry
  • Cancer Research

Background:

  • Bifunctional antisense oligonucleotides (BASOs) are splice-switching tools targeting pre-messenger RNA.
  • Alternative splicing of the pyruvate kinase M1/2 gene is crucial in cancer development.
  • Understanding nucleotide modifications can enhance BASO therapeutic efficacy.

Purpose of the Study:

  • To investigate the impact of modified nucleotides on pyruvate kinase M1/2 gene alternative splicing.
  • To evaluate the anticancer potential of modified BASOs in cancer cells.
  • To identify chemical modifications that improve BASO therapeutic properties.

Main Methods:

  • Synthesis and application of variously modified BASOs.
  • Real-time measurement of cancer cell proliferation and motility.
  • Analysis of alternative splicing regulation by BASOs.

Main Results:

  • Specific chemical modifications significantly enhanced BASO therapeutic properties.
  • Modified BASOs reduced cancer cell proliferation, induced cell death, and decreased motility.
  • β-L-RNA and unlocked nucleic acid modifications showed potent splicing regulatory and anticancer effects.

Conclusions:

  • Chemical modifications, particularly β-L-RNA and unlocked nucleic acid, improve BASO efficacy in splicing regulation and cancer therapy.
  • These modifications offer a promising strategy for developing novel oligonucleotide-based cancer treatments.
  • The study proposes efficient modifications for protein-binding oligonucleotides to enhance therapeutic outcomes.